Navigation Links
Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Date:8/31/2009

BASKING RIDGE, N.J., Aug. 31 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the results of a Phase 2a clinical trial of their lead product, the anticoagulant system REG1, were released at the European Society of Cardiology Congress in Barcelona, Spain. The results, detailed in a poster entitled, "First Clinical Application of an Actively Reversible Direct Acting Factor IXa inhibitor in Elective Percutaneous Intervention", were presented by Dr. Mauricio Cohen, lead investigator of the study from the University of Miami-Miller School of Medicine. The poster was presented on Sunday, August 30, 2009.

This was the first study to evaluate REG1 in a clinical setting involving percutaneous coronary intervention (PCI). REG1 is a two component system consisting of RB006, a direct FIXa inhibitor and RB007, the active, specific control agent for RB006. This phase 2a study (REVERSAL-PCI) was an open-label, randomized, multicenter study that evaluated feasibility and safety during elective PCI comparing the REG1 anticoagulant system with unfractionated heparin in patients with coronary artery disease. All 26 patients in the study received aspirin and clopidogrel as background therapy. The primary endpoint of the study was major bleeding within 48 hours. Important secondary endpoints were a composite of death, myocardial infarction or urgent target vessel revascularization within 14 days and pharmacodynamic measures. The three arms of the study were designed to measure both total and partial anticoagulant reversal, with all REG1 subjects undergoing planned early arterial catheter sheath removal.

The study demonstrated that the REG1 System enabled safe and effective PCI. All procedures were successfully completed in the REG1 cohorts with no signs of catheter or guidewire thrombosis. Coagulation parameters demonstrated effective, predictable and consistent ranges of anticoagulation during the study. Reversal of the anticoagulant effects of RB006 using RB007 was rapid, predictable and reproducible and permitted planned early arterial catheter sheath removal. The study also demonstrated that REG1 was well tolerated during PCI.

"The REVERSAL-PCI study represents the first study in which a reversible aptamer anticoagulation system was employed during an interventional cardiology procedure. These results demonstrate the potential for the use of the REG1 S-system in patients undergoing PCI", stated Dr Mauricio Cohen, the principle investigator for the study.

"This first clinical application of the REG1 System in PCI is a significant milestone in the development of this innovative and unique product. Based on these positive results, we can confidently advance to the next stage of development with the initiation of the 'RADAR' trial, our phase 2b study", stated Chris Rusconi, PhD, Chief Scientific Officer and Co-Founder of Regado Biosciences. President and CEO David J. Mazzo, PhD added, "We are delighted and honored to have the REVERSAL-PCI data accepted and presented at such a prestigious meeting as the European Society of Cardiology Congress".

ABOUT REGADO BIOSCIENCES: Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT THE REG1 SYSTEM: Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents, the first being a potent and highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006.

ABOUT APTAMERS: RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.

More information can be found at http://www.regadobio.com


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
2. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
3. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
4. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
5. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
6. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
7. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
8. Neurocrine Biosciences Presents Elagolix Data
9. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... LONDON , January 18, 2017 ... community to share research resources, has opened its first North ... . ... This marks an expansion for Ximbio following its launch in ... Cancer Research Technology (CRT), the commercialization arm of the foundation ...
(Date:1/18/2017)... 2017 After the recent election cycle, ... of cannabis both for medical and recreational purposes are shifting. ... to the use of cannabis, but the focus is coming ... Market Research, the North American legal cannabis market posted $6.7 ... year. The research projects sales will grow at a compound ...
(Date:1/18/2017)... , Jan. 18, 2017  Astellas Pharma Inc. ... ) today announced its participation in Access Accelerated, ... non-communicable disease (NCD) prevention, diagnostics and treatment in ... other leading pharmaceutical companies and in collaboration with ... International Cancer Control (UICC), Astellas will work towards ...
Breaking Medicine Technology:
(Date:1/18/2017)... VA (PRWEB) , ... January 18, 2017 , ... Dr. ... in family, cosmetic and implants dentistry. His modern dental practice has two convenient office ... as a 2017 Top Rated Dentist for the Alexandria area. This award ...
(Date:1/18/2017)... ... 18, 2017 , ... Rollerblade®, the worldwide leader in inline ... braking system that allows skaters of all levels to stop safely with more ... of beginner and intermediate skaters – learning how to brake with more balance ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – ... to choose the best drug option for each patient. Dentists have several general anesthesia ... overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to ... Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, Dr. ... and pass through tough times, Dr. Bernie Siegel energizes listeners to live life ...
(Date:1/17/2017)... Grove Village, IL (PRWEB) , ... January 17, ... ... for musicians and music enthusiasts at the National Association of Music Merchants (NAMM) ... January 19 – 22, 2017. , Etymotic’s ER•4® has long been the gold ...
Breaking Medicine News(10 mins):